WHO approval for Covaxin delayed again; final risk-benefit analysis likely on November 3
The WHO's decision on including Covaxin in its Emergency Use Listing was delayed again after the UN health agency sought clarifications from Bharat Biotech.
Stay updated with breaking news from Use Listing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The WHO's decision on including Covaxin in its Emergency Use Listing was delayed again after the UN health agency sought clarifications from Bharat Biotech.
The World Health Organisation’s Technical Advisory Group met on October 26 and decided that additional clarifications from Bharat Biotech are needed.
A WHO technical advisory group was reviewing data on Covaxin shot against COVID-19 today with a decision on its emergency use listing likely soon, a spokesperson said.
The World Health Organisation (WHO) said "additional clarifications" are needed from Bharat Biotech over its Covid-19 vaccine 'Covaxin' for its final assessment before it is recommended for emergency use.
A World Health Organization (WHO) technical advisory group on Tuesday reviewed data on Covaxin shot against Covid-19 with a decision on its emergency use listing likely soon, a spokesperson said. 'If all is in place and all goes well and if the committee is satisfied, we would expect a recommendation within the next 24 hours or so,' Margaret Harris said at a UN press briefing. Earlier this week, the global health organisation had said in a tweet that it is expecting one additional piece of